Department of Gastroenterology, Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
J Surg Oncol. 2024 Sep;130(4):714-723. doi: 10.1002/jso.27651. Epub 2024 Apr 17.
Robot-assisted gastrectomy (RG) has been shown to be safe and feasible in the treatment of gastric cancer (GC). However, it is unclear whether RG is equivalent to laparoscopic gastrectomy (LG), especially in the Western world. Our objective was to compare the outcomes of RG and LG in GC patients.
We reviewed all gastric adenocarcinoma patients who underwent curative gastrectomy by minimally invasive approach in our institution from 2009 to 2022. Propensity score matching (PSM) analysis was conducted to reduce selection bias. DaVinci Si platform was used for RG.
A total of 156 patients were eligible for inclusion (48 RG and 108 LG). Total gastrectomy was performed in 21.3% and 25% of cases in LG and RG, respectively. The frequency of stage pTNM II/III was 48.1%, and 54.2% in the LG and RG groups (p = 0.488). After PSM, 48 patients were matched in each group. LG and RG had a similar number of dissected lymph nodes (p = 0.759), operative time (p = 0.421), and hospital stay (p = 0.353). Blood loss was lower in the RG group (p = 0.042). The major postoperative complications rate was 16.7% for LG and 6.2% for RG (p = 0.109). The 30-day mortality rate was 2.1% and 0% for LG and RG, respectively (p = 1.0). There was no significant difference between the LG and RG groups for disease-free survival (79.6% vs. 61.2%, respectively; p = 0.155) and overall survival (75.9% vs. 65.7%, respectively; p = 0.422).
RG had similar surgical and long-term outcomes compared to LG, with less blood loss observed in RG.
机器人辅助胃切除术(RG)已被证明在治疗胃癌(GC)方面是安全且可行的。然而,在西方世界,RG 是否与腹腔镜胃切除术(LG)相当尚不清楚。我们的目的是比较 GC 患者接受 RG 和 LG 的治疗结果。
我们回顾了 2009 年至 2022 年期间在我院接受微创治疗的所有胃腺癌患者。采用倾向评分匹配(PSM)分析来减少选择偏倚。使用达芬奇 Si 平台进行 RG。
共有 156 名患者符合纳入标准(48 名 RG 和 108 名 LG)。LG 和 RG 中分别有 21.3%和 25%的患者行全胃切除术。pTNM II/III 期的频率分别为 48.1%和 54.2%,LG 和 RG 组之间无显著差异(p=0.488)。经过 PSM 后,每组匹配 48 例患者。LG 和 RG 的淋巴结清扫数量(p=0.759)、手术时间(p=0.421)和住院时间(p=0.353)相似。RG 组的出血量较低(p=0.042)。LG 组的主要术后并发症发生率为 16.7%,而 RG 组为 6.2%(p=0.109)。LG 和 RG 的 30 天死亡率分别为 2.1%和 0%(p=1.0)。LG 和 RG 两组的无病生存率(分别为 79.6%和 61.2%;p=0.155)和总生存率(分别为 75.9%和 65.7%;p=0.422)无显著差异。
与 LG 相比,RG 的手术和长期结果相似,并且 RG 的出血量更少。